Polysorbate 20 Fatty Acid Ester Distribution for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polysorbate 20 compositions in pharmaceutical formulations are prone to hydrolytic degradation, leading to the formation of free fatty acids, which results in visible and sub-visible particles, affecting the stability and shelf life of protein-based drugs.
Innovation Solution
Formulations with specific fatty acid ester distributions, such as those with reduced stearate, palmitate, and myristate esters and enriched short-chain fatty acid esters, are developed to minimize the formation of free fatty acid particles, thereby enhancing stability and shelf life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysorbate 20 is used in pharmaceutical formulations, then interfacial stresses are mitigated and protein stability is improved, but hydrolytic degradation occurs leading to free fatty acid particle formation
Solution Approach 1:
The patent modifies the fatty acid ester distribution parameters of polysorbate 20 by reducing longer-chain esters (stearate C18, palmitate C16, myristate C14) and enriching shorter-chain esters (caproate C6, caprylate C8, caprate C10, laurate C12). This parameter change in molecular structure reduces hydrophobicity and susceptibility to hydrolytic degradation, thereby reducing free fatty acid particle formation while maintaining protein stability protection
2Ease of operation
If standard polysorbate 20 composition is used, then surfactant functionality is achieved, but shelf life is reduced due to degradation and particle formation
Solution Approach 1:
The patent changes the compositional parameters of polysorbate 20 by establishing specific concentration ranges for different fatty acid esters: caproate 1-10%, caprylate 1-10%, caprate 1-10%, laurate 40-60%, myristate 10-30%, palmitate 5-20%, and stearate 1-10%. This optimized parameter distribution maintains surfactant functionality while reducing hydrolytic degradation rate, thereby extending shelf life
Solution Approach 2:
The patent converts the inherent vulnerability of polysorbate 20 (prone to hydrolytic degradation) into a benefit by strategically selecting fatty acid ester types. By enriching shorter-chain esters that are less susceptible to degradation, the formulation transforms a potential weakness into an advantage, achieving both functionality and extended stability
3Stability of the object's composition
If longer-chain fatty acid esters are present in polysorbate 20, then hydrophobic properties are enhanced, but solubility in aqueous solution decreases and particle formation increases
Solution Approach 1:
The patent optimizes the hydrophobicity parameter by controlling the distribution of fatty acid ester chain lengths. It maintains moderate hydrophobicity through balanced composition: shorter-chain esters (caproate C6, caprylate C8, caprate C10, laurate C12) provide aqueous solubility, while longer-chain esters (myristate C14, palmitate C16, stearate C18) provide hydrophobic protection. This parameter balancing achieves optimal solubility without sacrificing protective functionality
Solution Approach 2:
The patent applies local quality differentiation by having different fatty acid ester types perform different functions: shorter-chain esters primarily provide solubility and resistance to hydrolytic degradation, while longer-chain esters provide hydrophobic shielding. This functional differentiation within the mixture optimizes both solubility and protective capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The specific fatty acid ester distributions in the polysorbate 20 compositions delay the formation of free fatty acid particles, reducing waste and extending the shelf life of pharmaceutical formulations by maintaining stability and preventing particle formation.
Implementation Method 1
Amphiphilic properties allow PS20 to interact with liquid-air and liquid-solid interfaces, shielding protein therapeutics from agitation-induced aggregation
Implementation Method 2
Polysorbate 20 (PS20) is a nonionic surfactant used in protein formulations, for example, to mitigate interfacial stresses
Implementation Method 3
PS20 can hydrolytically degrade in biopharmaceutical drug products, causing the appearance of visible and sub-visible particles. Enzymes (for example, lipases, esterases, etc.) are believed to cleave PS20 at the ester bond resulting in the formation of free fatty acids (FFAs) and free head groups or polyols
Data Source
AI summary
The present disclosure provides polysorbate 20 compositions with particular fatty acid ester concentrations. In some embodiments, they may be used in pharmaceutical formulations, for example, to improve stability.